20.02.2017 Formerly known as Debiopharm Diagnostics, Debiopharm Innovation Fund has become the strategic investment fund of the Group based in Lausanne. It focuses its investments in young innovative companies and startups with opportunities in Patient Care.
As seen it its latest newsletter, Debiopharm has made important changes in its investment strategy. In the past the group has invested in startups such as Coorpacademy or Skiioo in Western Switzerland via its Debiopharm Investment company. Today this team is fully dedicated to support the sustainable growth of the Group and focuses its investment efforts in more mature ventures.
Startups with investment opportunities in patient care must turn today to the Debiopharm Innovation Fund, the strategic investment fund of the Debiopharm Group which invests in three specific areas:
- Smart data (pilot or early commercial stage),
- Therapeutics (discovery and early development)
- Diagnostics (development stage).
The focus is set on technologies related to Debiopharm Group’s therapeutic areas of interest, oncology and infectious disease. The Innovation Fund’s objective is to make strategic investments in innovative companies with technologies and business models that change the way drugs are developed and patients treated.
The Innovation Fund brings value to its portfolio companies through Debiopharm knowledge in medicine, pharmaceutical development, regulatory/reimbursement aspects, management and expertise in bringing products to market, driving portfolio investments into successful exits.
Debiopharm Innovation Fund aims at completing into two to three investments per year, with a participation in each company not to exceed 25%, and with representation on the Board of Directors. If you have an investment opportunity that falls into smart data, therapeutics or diagnostics, don’t hesitate to check the company website to learn more about the investment criteria and contact them.